| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director
1 company
Joel Lewis is President and CEO at GALT. From January 2019 to January 2026, the filings on record show 5 open-market purchases and 8 sales. Joel Lewis's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.8M at current prices.
Historically, Joel Lewis's trades have earned a middling insider score of 67/100 across 14 rated trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of -14.5%.
The GALT filings lean toward selling, a net 197,412 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 667 | $4.82 | $3,214.07 | +1.0% | |
| Feb 7, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 1,000 | $4.48 | $4,484.10 | +1.6% | |
| Jan 29, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 1,000 | $4.81 | $4,805.00 | +1.6% |